Dashti N, Alaupovic P, Knight-Gibson C, Koren E
Lipoprotein and Atherosclerosis Research Program, Oklahoma Medical Research Foundation, Oklahoma City.
Biochemistry. 1987 Jul 28;26(15):4837-46. doi: 10.1021/bi00389a035.
The purpose of this study was to test the use of human hepatocarcinoma HepG2 cells as a model for studying the formation and secretion of human hepatic lipoproteins. To this end, we determined the rate of accumulation and percent composition of neutral lipids and apolipoproteins in the culture medium of HepG2 cells and isolated and partially characterized the apolipoprotein B (ApoB) containing lipoprotein particles. The rates of accumulation in the medium of HepG2 cells, grown in minimum essential medium during a 24-h incubation, of triglycerides, cholesterol, and cholesterol esters expressed as microgram/(g of cell protein X h) were 373 +/- 55, 167 +/- 14, and 79 +/- 10, respectively; the secretion rates for apolipoproteins B, A-I, E, A-II, and C-III were 372 +/- 36, 149 +/- 14, 104 +/- 13, 48 +/- 4, and 13 +/- 1 microgram/(g of cell protein X h), respectively. The major portion of ApoB was present in very low density lipoproteins (VLDL) and low-density lipoproteins (LDL) (84%), with the remainder occurring in high-density lipoproteins (HDL) (16%). Approximately 10-13% of ApoA-I and ApoA-II were present in VLDL and LDL, while 60% of ApoE occurred in HDL and 40% in VLDL and LDL. To separate ApoB-containing lipoproteins, secreted lipoproteins were fractionated by either sequential immunoprecipitation or immunoaffinity chromatography with antibodies to ApoB and ApoE. Results showed that 60-70% of ApoB occurred in the culture medium as lipoprotein B (LP-B) and 30-40% as lipoprotein B:E (LP-B:E). Both ApoB-containing lipoproteins represent polydisperse systems of spherical particles ranging in size from 100 to 350 A for LP-B and from 200 to 500 A for LP-B:E. LP-B particles were identified in VLDL, LDL, and HDL, while LP-B:E particles were only present in VLDL and LDL. The major neutral lipid of both ApoB-containing lipoproteins was triglyceride (50-70% of the total neutral lipid content); cholesterol and cholesterol esters were present in equal amounts. The LP-B:E particles contained 70-90% ApoB and 10-30% ApoE. The ApoB was identified in both types of particles as B-100. A time study on the accumulation of ApoB-containing lipoproteins showed that LP-B particles were secreted independently of LP-B:E particles.
本研究的目的是测试使用人肝癌HepG2细胞作为研究人肝脂蛋白形成和分泌的模型。为此,我们测定了HepG2细胞培养基中中性脂质和载脂蛋白的积累速率及百分比组成,并分离并部分表征了含载脂蛋白B(ApoB)的脂蛋白颗粒。在最低限度基本培养基中培养24小时的HepG2细胞培养基中,甘油三酯、胆固醇和胆固醇酯的积累速率以微克/(克细胞蛋白×小时)表示,分别为373±55、167±14和79±10;载脂蛋白B、A-I、E、A-II和C-III的分泌速率分别为372±36、149±14、104±13、48±4和13±1微克/(克细胞蛋白×小时)。ApoB的主要部分存在于极低密度脂蛋白(VLDL)和低密度脂蛋白(LDL)中(84%),其余部分存在于高密度脂蛋白(HDL)中(16%)。约10 - 13%的ApoA-I和ApoA-II存在于VLDL和LDL中,而60%的ApoE存在于HDL中,40%存在于VLDL和LDL中。为了分离含ApoB的脂蛋白,分泌的脂蛋白通过用抗ApoB和ApoE抗体进行顺序免疫沉淀或免疫亲和色谱进行分级分离。结果表明,60 - 70%的ApoB以脂蛋白B(LP-B)的形式存在于培养基中,30 - 40%以脂蛋白B:E(LP-B:E)的形式存在。两种含ApoB的脂蛋白均代表球形颗粒的多分散系统,LP-B的大小范围为100至350 Å,LP-B:E的大小范围为200至500 Å。LP-B颗粒在VLDL、LDL和HDL中均有鉴定,而LP-B:E颗粒仅存在于VLDL和LDL中。两种含ApoB的脂蛋白的主要中性脂质是甘油三酯(占总中性脂质含量的50 - 70%);胆固醇和胆固醇酯含量相等。LP-B:E颗粒含有70 - 90%的ApoB和10 - 30%的ApoE。两种颗粒中的ApoB均鉴定为B-100。对含ApoB脂蛋白积累的时间研究表明,LP-B颗粒的分泌独立于LP-B:E颗粒。